Cytosorbents Corporation

Thank you for standing by. My name is Catherine, and I will be your conference operator today. At this time, I would like to welcome everyone to the Citus Harbens Corporation third quarter 2024 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remark, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to redraw your question, press star one again. Thank you. I would now like to turn the call over to Investor Relations Consultant, Adana Alexander. Please go ahead.

Thank you, Catherine, and good afternoon, everyone. Welcome to SIDUS Auburn's Third Quarter 2024 Financial and Operating Results Conference Call. Joining me today from the company for the prepared remarks are Dr. Philip Chan, Chief Executive Officer, and Pete Mariani, Chief Financial Officer. For the Q&A portion of the call, Dr. Chan and Mr. Mariani will be joined by Vincent Caponi, President and Chief Operating Officer, Dr. Micah Delia-Giris, Chief Medical Officer, Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of Fattest Lobos Europe, and Christian Kramer, Senior Vice President of Business Development. Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today, and therefore we refer you to a more detailed discussion of our performance represented by management, include estimates today as of November 7th, 2024, and we assume no obligation to abate these projections in the future as market conditions change. During today's call, we will have an overview presentation covering the operating and financial highlights for the third quarter of 2024. Following the presentation, we will open the line to your questions during the live Q&A session with the rest of the management team. And now, it is my pleasure to turn the call over to Dr. Philip Chan.

Thank you very much, Adana, and good afternoon and welcome everyone to our third quarter 2024 earnings call.